FSD Pharma (@FsdPharma) (#Nasdaq: $HUGE | #CSE: $HUG) Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA [https://t.co/szClMWncy2]

#investing #stocks #stockmarket #trading #investors #news #business #capitalmarket https://t.co/qV7Ncy6Vdx